Posted by Michael Wonder on 10 Nov 2020
ICER provides second update to pricing models for remdesivir as a treatment for COVID-19
10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the totality of evidence no longer supports an assumption of survival benefit from remdesivir; however, new data from US based ACTT-1 trial does support savings on insurer payment for hospital services.
The ICER today released updated analyses to inform public debate of pricing for remdesivir (Veklury, Gilead Sciences) for the treatment of COVID-19.
